(USD) | Dec 2022 | Q/Q |
---|---|---|
Revenue | 81K | -14% |
Operating Income | - | - |
Operating Expenses | 52.1MM | +49% |
Net Income | -53MM | +48% |
R&D | - | - |
G&A | - | - |
Interest Expense | - | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2024 Earnings Call Transcript May 2, 2024 TG Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to the TG Therapeutics Conference Call and Webcast. At this time all participants are […]
TG Therapeutics, Inc. ( NASDAQ:TGTX ) shareholders will have a reason to smile today, with the analysts making...
The company raised guidance for sales of its drug for relapsing multiple sclerosis.
TG Therapeutics ( NASDAQ:TGTX ) First Quarter 2024 Results Key Financial Results Revenue: US$63.5m (up by US$55.7m from...
Despite a net loss, TG Therapeutics Inc reports significant revenue increases and strategic advancements in Q1 2024, setting a positive trajectory for the year.
Q1 2024 TG Therapeutics Inc Earnings Call
Comprehensive Analysis of TG Therapeutics' First Quarter Financial Performance
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -133.33% and 15.59%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
First quarter 2024 BRIUMVI U.S. net revenue of $50.5 million, representing >25% quarter over quarter growth Total revenue for Q1 2024 of $63.5 million, including a $12.5 million milestone payment for BRIUMVI launch in first EU country New BRIUMVI prescriptions to the TG hub of over 1,250 for Q1 2024, representing >25% growth quarter over quarter Conference call to be held today, May 1, 2024, at 8:30 AM ET NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Compan
Conference call to be held tomorrow, Wednesday, May 1, 2024, at 8:30 AM ETNEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held tomorrow, Wednesday, May 1, 2024, at 8:30 AM ET to discuss results for the first quarter of 2024 and provide a business outlook for 2024. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U